DarioHealth Corp DRIO.OQ DRIO.O is expected to show a fall in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
The New York City-based company is expected to report a 23.7% decrease in revenue to $5.665 million from $7.42 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for DarioHealth Corp is for a loss of $4.90 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for DarioHealth Corp is $25.00, about 44% above its last closing price of $13.99
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -4.75 | -4.67 | -3.60 | Beat | 22.9 |
Mar. 31 2025 | -2.34 | -2.33 | -2.80 | Missed | -20 |
Dec. 31 2024 | -6.78 | -6.67 | -1.80 | Beat | 73 |
Sep. 30 2024 | -5.52 | -5.47 | -5.00 | Beat | 8.5 |
Jun. 30 2024 | -10.94 | -11.10 | -1.60 | Beat | 85.6 |
Mar. 31 2024 | -9.52 | -8.10 | -4.00 | Beat | 50.6 |
Dec. 31 2023 | -10.80 | -11.07 | -10.00 | Beat | 9.6 |
Sep. 30 2023 | -9.53 | -9.20 | -9.80 | Missed | -6.5 |
This summary was machine generated November 3 at 14:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)